Back to Search
Start Over
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
- Source :
- Scientia, Neurology and therapy, vol 11, iss 2
- Publication Year :
- 2022
-
Abstract
- COVID-19; Ofatumumab; Vaccination COVID-19; Ofatumumab; Vacunación COVID-19; Ofatumumab; Vacunació Introduction The SARS-CoV-2 pandemic necessitated better understanding of the impact of disease-modifying therapies on COVID-19 outcomes and vaccination. We report characteristics of COVID-19 cases and vaccination status in ofatumumab-treated relapsing multiple sclerosis (RMS) patients. Methods COVID-19 data analyzed were from the ongoing, open-label, long-term extension phase 3b ALITHIOS study from December 2019 (pandemic start) and post-marketing cases from August 2020 (ofatumumab first approval) up to 25 September 2021. COVID-19 cases, severity, seriousness, outcomes, vaccination status, and breakthrough infection were evaluated. Results As of 25 September 2021, 245 of 1703 patients (14.4%) enrolled in ALITHIOS receiving ofatumumab (median exposure: 2.45 years) reported COVID-19 (confirmed: 210; suspected: 35). Most COVID-19 was of mild (44.1%) or moderate (46.5%) severity, but 9% had severe/life-threatening COVID-19. There were 24 serious cases (9.8%) with 23 patients hospitalized; 22 recovered and 2 died. At study cut-off, 241 patients (98.4%) had recovered or were recovering or had recovered with sequelae and 2 (0.8%) had not recovered. Ofatumumab was temporarily interrupted in 39 (15.9%) patients. Before COVID-19 onset, IgG levels were within the normal range in all COVID-19–affected patients, while IgM was
- Subjects :
- ALITHIOS
Vaccine Related
Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting [DISEASES]
B-cell therapy
Cancer
Anti-CD20 THERAPY
Anti-CD20 therapy
SARS-CoV-2
Prevention
Vaccination
Otros calificadores::Otros calificadores::/terapia [Otros calificadores]
COVID-19
Ofatumumab
enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente [ENFERMEDADES]
Emerging Infectious Diseases
Infectious Diseases
Good Health and Well Being
Neurology
Other subheadings::Other subheadings::/therapy [Other subheadings]
Relapsing multiple sclerosis
Avaluació de resultats (Assistència sanitària)
Immunization
Neurology (clinical)
Infection
Esclerosi múltiple - Tractament
Post-marketing
COVID-19 (Malaltia) - Vacunació
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Scientia, Neurology and therapy, vol 11, iss 2
- Accession number :
- edsair.doi.dedup.....6b835b539b7d244ee2268205afb91ca8